{
    "symbol": "SUPN",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-09 20:24:12",
    "content": " Total revenues were $152.5 million, representing a 16% increase over the first quarter of last year. And adjusted non-GAAP operating earnings were $28 million, an 11% increase over the first quarter of last year. Regarding GOCOVRI, we are pleased with the performance of the GOCOVRI during its first full quarter under Supernus, with net sales for the product reaching $22.6 million, representing a 28% increase compared to the $17.7 million reported by Adamas in the first quarter in 2021. For the first quarter of 2022, net product sales have Oxtellar XR were $28 million, essentially unchanged compared to the same period last year, while net product sales of Trokendi XR were $63 million down from $72 million last year. Total revenue for the first quarter of 2022 was $152.5 million, a 16% increase compared to $130.9 million in the same quarter last year. For the first quarter of 2022, combined R&D and SG&A expenses were $111.3 million as compared to $95.7 million for the same period in 2021. Operating earnings on a GAAP basis for the first quarter of 2022 was $2 million, as compared to $13.2 million for the same period in 2021. Adjusted operating earnings was $28 million, an increase of 11% compared to $25.2 million for the first quarter of 2021. This favorable Income Tax Benefit resulted in a net tax benefit of $10.9 million for the first quarter of 2022, reflecting this tax benefit, GAAP net earnings were $25.6 million for the first quarter of 2022 or $0.43 per diluted share compared to $5.7 million or $0.11 per diluted share in the same period last year."
}